P
orcine reproductive and respiratory syndrome (PRRS) is characterized by respiratory distress in piglets and reproductive failure in sows (3, 6) . The disease was detected in North America in 1987 (9, 11) and in Europe in 1990 (25) , and it has now become a well-recognized global swine disease (1, 6, 10, 23, 35) . PRRS has devastated the swine industry by causing tremendous economic losses throughout the world and is now considered to be one of the most important diseases in countries with intensive swine industries (16, 20) .
The causative agent, PRRS virus (PRRSV), is a positive-strand RNA virus which belongs to the family Arteriviridae, together with lactate dehydrogenase-elevating virus (LDV) of mice, equine arteritis virus (EAV), and simian hemorrhagic fever virus (SHFV) (5, 31) . PRRSV isolates can be divided into the European (EU) and the North American (NA) genotypes, which are genetically and antigenically different (4, 21, 22) . Currently, a limited number of PRRSV vaccines, either modified live or killed vaccines, are commercially available and efficacious. These vaccines contain a single PRRSV strain and are not fully protective against genetically diverse field strains in most cases (17) . In addition, outbreaks of atypical or acute PRRS, a severe form of PRRS characterized by abortion and high mortality in pregnant sows, were reported for vaccinated pigs (2, 18) . Since May 2006, a highly virulent form of PRRSV (highly pathogenic PRRSV [HP-PRRSV]), characterized by high fever and high mortality in pigs of all ages, has severely affected the pork industry of China (14, 32, 34) . Therefore, there is a strong need for a new vaccine to be developed against emerging HP-PRRSV strains.
HP-PRRSV strain TJ was originally isolated from a piglet that died of a "high fever" in Tianjin, China, in 2006, and it had the same characteristics as those of other HP-PRRSV strains observed in China (13) . HP-PRRSV strain TJ was culturally passaged on MARC-145 cells for attenuation so that it could be used for the development of a modified live virus (MLV) vaccine. The purposes of this study were to attenuate a virulent HP-PRRSV TJ strain, genetically characterize the attenuated (92nd passage of strain TJ) HP-PRRSV strain TJM, and evaluate its virulence and immunogenicity in host animals.
MATERIALS AND METHODS

Cells and viruses.
The MARC-145 cell line (derived from African green monkey kidney cells) was employed for viral propagation and titration. PRRSV strain TJ (GenBank accession no. EU860248) was isolated and maintained in our laboratory as previously described (13) .
Viral culturing and attenuation. PRRSV strain TJ was continuously passaged on MARC-145 cells and plaque cloned every 5 to 10 passages. For plaque cloning, the virus suspension was serially 10-fold diluted, and 200 l of virus was inoculated onto MARC-145 monolayers in 6-well microtiter tissue culture plates. After 1 h of incubation at 37°C, the cell monolayers were then overlaid with minimal essential medium (MEM) (2ϫ) containing 2% low-melting agarose (Cambrex, Rockland, ME) and 4% fetal bovine serum and then incubated for 72 h to 96 h at 37°C with 5% CO 2 . Single plaques were selected, and the viruses were further passaged. The 92nd passage of PRRSV strain TJ was harvested and designated HP-PRRSV strain TJM, which was characterized and evaluated in this study.
Sequencing of HP-PRRSV TJ.
RNAs were extracted from different TJ passages (F3 [third passage], F10, F15, F19, F31, F51, F78, and F92 [TJM]), and reverse transcription (RT)-PCR was performed as previously described (12, 13) , using forward and reverse primers (Table 1) which amplified the complete nsp2 and ORF5 sequences. PCR products were cloned into the pMD18-T vector (TaKaRa, Japan) and sequenced, and at least three clones for each fragment were sequenced. Multiple-sequence alignments were carried out by using Lasergene1 (DNASTAR Inc., Madison, WI) sequence analysis software.
Animal infection model. A total of 45 pigs, 3 weeks of age, from a pig farm were used in the study. All animals were confirmed to be free of PRRSV and porcine circovirus type 2 (PCV2) infections by use of commercial enzyme-linked immunosorbent assay (ELISA) kits for the detection of antibodies against PRRSV (Idexx Laboratories Inc.) and PCV2 (Ingezim circovirus IgG/IgM kit; Ingenasa, Spain) and by RT-PCR or PCR for viral nucleic acid detection. The animals were also negative for classical swine fever virus, porcine parvovirus, pseudorabies virus, swine influenza virus, and Mycoplasma hyopneumoniae infections by serological methods and/or RT-PCR or PCR. The pigs were transported to biological safety level 2 (BSL2) facilities at Jilin Veterinary Biologicals 1 week prior to virulent HP-PRRSV challenge. Forty-five piglets were randomly divided into 3 groups ( Table 2 ). Piglets of group 1 (n ϭ 20) were inoculated intramuscularly (i.m.) with 10 5.0 50% tissue culture infective doses (TCID 50 ) of strain TJM. Group 2 (n ϭ 20) was not immunized and served as challenge controls. At 28, 60, 120, and 180 days postimmunization (dpi), five pigs each from groups 1 and 2 were randomly selected and challenged with 3 ϫ 10 4.0 TCID 50 per pig of the third-passage harvest of the HP-PRRSV TJ strain (TJ-F3, which was still virulent to pigs). The challenge was given both i.m., in a 1-ml volume, and intranasally (i.n.), in a 2-ml volume. After challenge, clinical signs, including coughing, dyspnea, anorexia, lameness, shivering, and fever, were observed and recorded daily prior to feeding. All the animals were euthanized at 21 days postchallenge (dpc).
Group 3 (n ϭ 5) remained as a not-immunized and not-challenged strict control (no vaccine and no challenge) during the experiment.
Serological examination. PRRSV-specific antibody responses were analyzed with serum collected at 0, 7, 14, 21, 28, 60, 90, 120, 150, and 180 dpi, using a commercial ELISA kit (Idexx Laboratories Inc., Westbrook, ME) according to the manufacturer's instructions. The PRRSV-specific antibody level was reported as an S/P ratio, and the serum samples were considered positive if the S/P ratio was 0.4 or higher. In addition, serum neutralization assays were performed, as previously described (26, 33) , to detect the presence and duration of anti-PRRSV neutralizing antibodies, and the virus used in the neutralization assay was PRRSV strain TJM.
Viremia assessment. To determine if the animals were viremic, virus isolation was done by inoculating MARC-145 cells with the respective serum samples collected during the vaccination and infection procedures. The MARC-145 culture plates subsequently inoculated with serum from infected animals and controls were observed microscopically for 5 days for PRRSV-specific cytopathic effects (CPEs). Subsequently, virus titers in cell cultures for each virus-positive serum sample were determined by a microtitration infectivity assay and recorded as TCID 50 /ml according to the Reed-Muench method, as previously described (12, 28) . After 5 days of incubation, an indirect fluorescent antibody test was performed to test the virus titer further. The cell monolayers were fixed with cold ethanol for 20 min, and the ethanol was then removed. The plates were air dried and washed with phosphate-buffered saline (PBS). Polyclonal antibodies of strain TJM were diluted in PBS with a 1:100 dilution, 0.1 ml of which was placed into virus-infected wells, followed by incubation for 45 min at 37°C in a humid chamber. The plates were washed 3 times with PBS, followed by the addition of 50 l of an appropriate dilution of fluorescein-conjugated rabbit anti-porcine IgG per well. After another 30 min of incubation, the plates were washed again and observed under a fluorescence microscope for specific cytoplasmic/perinuclear fluorescence.
Gross pathology and histopathology. At necropsy, lung, spleen, kidney, liver, heart, tonsil, lymph nodes, and brain were examined, and the lungs were harvested for histopathology following hematoxylin and eosin (H&E) staining, as described previously (27) .
RESULTS
Deletion of 120 amino acids in the nsp2 region of TJ-derived
viruses. An analysis of the sequence of RNA extracted from different passages (e.g., F3, F10, F15, F19, F31, F51, F78, and F92) of HP-PRRSV strain TJ identified a deletion of a large piece of the nsp2 region. This deleted genetic sequence encodes 120 amino acids (aa) at amino acid positions 628 to 747 according to the sequence of standard PRRSV strain VR-2332, and the deletion occurred in the F15 passage and the following passages (Fig. 1) . The serum was collected from the blood samples of piglets immunized with TJM at F92 at 7 dpi (Table 3) . The viral RNA extracted from the serum was amplified by RT-PCR, the sequence was analyzed, and the results showed that the 120-aa deletion was still present (Fig. 1) . Antibody responses in immunized piglets. Antibody detection using ELISA showed that all immunized piglets developed an anti-PRRSV antibody response by 14 dpi. At 60 and 90 dpi, the S/P ratio of antibody tests reached the highest level and then gradually decreased. However, the S/P ratio, an indication of a serological positive response, was still above 0.4 at 180 dpi. No PRRSV-specific antibodies were detected in the control animals prior to the challenge ( Table 5 ).The results of virus neutralization assays showed that PRRSV-specific neutralizing (SN) antibodies were not detectable at 28 dpi. The SN titer was first detected at 60 dpi, reached the highest level at 120 dpi, and then started to decrease. All control animals (no-vaccine, challenged group) were negative by SN antibody tests prior to the challenge (Table 5) . Additionally, antibody responses were negative for all five strict-control pigs (no-vaccine, no-challenge group) in the course of this study.
Clinical assessment of pigs postimmunization and postchallenge. After immunization, all piglets did not show any clinical signs of PRRS, indicating the attenuation of strain TJM. After challenge, pigs in group 1 (vaccine-treated, challenged group) did not show any overt clinical signs or low gains of body weight. However, all control pigs in group 2 (no-vaccine, challenged group) had various disease manifestations starting at as early as 2 dpc, including persistently high fever (Ն41.0°C) (Fig. 2) , anorexia, chemosis, skin cyanosis, coughing, shivering, or lameness. Most importantly, 3/5, 3/5, 2/5, and 2/5 control pigs died between days 8 and 20 postchallenge when the challenge was given at 28, 60, 120, and 180 dpi, respectively. None of immunized pigs showed high body temperatures or clinical diseases when challenges were given at 28, 60, or 120 dpi, and only 1/5 immunized pigs developed fever and had mild clinical signs when the challenge was given at 180 dpi (Table 6 ). Compared to the control pigs in group 2, the immunized pigs in group 1 gained weight at a significantly higher rate (P Ͻ 0.05) (Fig. 3) . In the course of the study, pigs in group 3 (no-vaccine, no-challenge group) had no clinical abnormalities.
Viremia in challenged piglets. All immunized pigs were PRRSV negative at the time of challenge (Table 7) . After challenge, viremia was not detected in all immunized animals that were challenged at 28, 60, or 120 dpi; in the group that was challenged at 180 dpi, 1 pig was viremic at 7 and 10 dpc, and the other 4 pigs were negative postchallenge. In contrast, viruses were recovered from all control animals in group 2 in all these challenges, up to 21 dpc ( Table 7) . The virus titers in control pigs were significantly higher (P Ͻ 0.05) (Fig. 4) .
Gross pathological and histopathological changes. Pathological lesions were found in all control pigs in group 2 at necropsy, including mainly interstitial pneumonia, enlarged lymph nodes, and a few blood spots on the kidney. In immunized pigs, no pathological damage was found when challenges were given at 28, 60, or 120 dpi. When the pigs were challenged at 180 dpi, 1 out 5 immunized pigs had mild interstitial pneumonia. Under microscopic examination, all the lungs from control pigs exhibited features that are characteristic of acute PRRSV infection, including collapsed alveoli with an infiltration of macrophages and an accumulation of immature lymphocytes in the interstitium (Fig. 5) . None of immunized pigs developed interstitial pneumonia when challenges were conducted at 28, 60, or 120 dpi, but after the challenge at 180 dpi, 1 out of 5 immunized pigs showed mild interstitial pneumonia in the lungs.
DISCUSSION
Since May 2006, a new highly pathogenic porcine reproductive and respiratory syndrome has been epizootic in major pig-producing areas of China. Studies have confirmed that the causative agent of this clinical outbreak was an HP-PRRSV strain, with a genomic marker consisting of a 30-aa deletion in nsp2 (14, 32, 34) . It has devastated the swine industry of China by causing tremendous economic losses. Vaccination is not the only way to prevent infectious diseases, but it is the most effective and practical method. Live attenuated PRRSV vaccines have been, and will continue to be, a valuable tool in PRRS disease control (19 
a SV indicates the virus from the serum samples of pigs immunized with F92 virus (TJM).
TABLE 5 Level of antibody responses in immunized piglets
PRRSV antibody
No. of piglets with antibody response/total no. of piglets immunized at dpi: (33), and these two vaccines could provide effective protection in young pigs against the virulent parental virus at 28 dpi. Here, we described a newly developed PRRSV MLV vaccine candidate, HP-PRRSV strain TJM, obtained by 92 passages of HP-PRRSV strain TJ on MARC-145 cells, which was efficacious in the prevention of infection and clinical disease caused by the parental TJ virus, and for the first time, we described the duration of immunity of the vaccine against HP-PRRSV challenge. In this study, piglets immunized with TJM were effectively protected against a lethal PRRSV challenge. The antibody response detected by ELISA showed that the S/P ratio was above 0.4 (an indication of a positive serological response to PRRSV) in all immunized animals from day 14 to day 180 postimmunization. However, the titer of neutralizing antibodies throughout the study was modest; this result was identical to those described previously for other experiments (24, 30) . Because the level of PRRSV antibody cannot reflect immunization protection completely, we challenged immunized pigs with HP-PRRSV at days 28, 60, 120, or 180 postimmunization, with the aim to measure the duration of immunity of the candidate vaccine (TJM strain). The results demonstrated that the immunized piglets were completely protected, with no clinical symptoms and pathological lesions observed and no viremia detected, when the challenges were conducted at days 28, 60, and 120 postimmunization. After challenge at 180 dpi, all 5 immunized piglets survived, although 1 of them showed mild clinical signs and was viremic, which might due to the low SN titers in the animals prior to the challenge (15) . Prior to challenge at day 28 postimmunization, all immunized pigs were SN antibody negative but were completed protected against lethal challenge, suggesting that a synergetic cellular immune response may have been involved. In addition, the results indicated that candidate vaccine strain TJM could provide complete protection for at least 4 months. Prior to this study, an intermediate TJ passage (TJ-F19) was used to inoculate piglets at a dose of 10 5.0 TCID 50 . Three out of 10 piglets developed mild dyspnea, and a histological examination of the lungs revealed moderate and mild lesions. However, piglets inoculated with TJ-F51 had no clinical symptoms during the entire experimental period, and no lung lesions were observed. These results indicated that the virulence of strain TJ decreased as it was continually passaged in tissue cultures and became attenuated at least at the 51st passage (TJ-F51). We have evaluated the effect of TJM (TJ-F92) by a 10-fold overdose inoculation in 28-day-old pigs, and the results showed no clinical signs, and the weight gain was similar to that of the no-inoculation control group (our unpublished data).
The nsp2 region is recognized as the most variable region in the genome of PRRSV and can endure a number of mutations, insertions, and deletions (7, 29) . In this study, the genome of nsp2 was cloned and sequenced at various passage stages (e.g., F3, F10, F15, F19, F31, F51, F78, and F92). From the 15th passage (F15), the harvested viruses of the TJ strain had a new subpopulation missing a 120-aa fragment in the nsp2 region (aa 628 to 747 according to the sequence of PRRSV strain VR-2332). By plaque cloning, we subcloned the virus from F16 and obtained the F19 subpopulation, which contained only the virus missing the 120 aa in nsp2, and further confirmed that the deletion remained through the F92 passage (TJM strain). After TJM was inoculated into pigs, the virus was reisolated from the serum sample, and sequence analysis demonstrated that the isolated virus had the same deletion of 120 aa at the same sites in the nsp2 region. In addition, other studies showed that the 120-aa deletion was maintained in serum after five back passages in pigs (data not shown). These results clearly indicated that the deletion in the nsp2 region became permanent and stable in the attenuated virus. 196 mutation was identical with that of HUN4/HUN4-F112, which can be used as a molecular marker to differentiate antibody responses generated against the HUN4-derived vaccine or against wild-type PRRSVs and NA-type vaccines by monoclonal antibody (MAb) 53D8 (33) . Using TMHMM 2.0 online software to predict the transmembrane helix of the GP5 protein, we found that there were 3 transmembrane regions (aa 15 to 32, 66 to 88, and 103 to 125) and 2 transmembrane regions (aa 66 to 88 and 103 to 125) in strains TJ and TJM, respectively, and the F23S mutation may cause the difference and further affect the immunology function of GP5 (data not shown).
The development of a vaccine that can differentiate infected and vaccinated animals (DIVA) is a new challenge in the design of a vaccine against porcine reproductive and respiratory syndrome virus. In this study, we demonstrated that PRRSV TJM, generated by means of passaging on MARC-145 cells, contained a unique 120-aa deletion in nsp2. The virus was ultimately attenuated and is a good candidate for vaccines against HP-PRRSV. Furthermore, the use of this vaccine will allow us to differentiate the TJ-derived vaccine from wild-type PRRSVs and NA-type vaccines, including HP-PRRSV vaccine strains JXA1-R and HUN4-F112.
